Latest Safety News

Hot Chili Limited is accelerating development at its La Verde copper-gold deposit in Chile, reporting strong drilling results and securing an additional US$15 million via an amended royalty agreement with OR Royalties. The company is progressing environmental assessments and pre-feasibility studies for the broader Costa Fuego project while maintaining a robust cash position.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Volt Group has delivered a record $5.1 million in half year revenue receipts for HY26, more than doubling prior year results, driven by strong contributions from its 4D Delta acquisition and solid performances across Wescone and EcoQuip.

Advanced Braking Technology (ASX: ABV) posted a record $6.2 million in product sales for Q4 FY26, lifting full-year revenue 22.7% to $23.5 million. The company’s autonomous BRAKEiQ system advanced key milestones as international engagement expanded.

Lunnon Metals boosts cash to $22.2 million as Lady Herial mining wraps up, launching a record $13 million exploration budget targeting up to 2.4 million ounces of gold at Foster-Baker.

Perseus Mining reported a robust June quarter with 109,013 ounces of gold produced at an AISC of US$1,941/oz, record FY26 cashflows of US$769 million, and Nyanzaga Gold Project 67% complete on track for January 2027 production.

Emu NL has launched its largest drilling program yet at the Georgetown Copper Project, backed by a recent A$2.98 million capital raise. The company aims to systematically test high-priority copper targets at Yataga Valley following improved geological modeling.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Nickel Industries delivered a record US$45.7 million Adjusted EBITDA from its Hengjaya Mine, launched first mixed hydroxide precipitate production at its ENC HPAL project, and secured major HPAL asset acquisitions, positioning itself for growth across the nickel value chain.

Centaurus Metals has made significant strides towards a Final Investment Decision for its Jaguar Nickel Sulphide Project, securing strong debt financing interest, critical infrastructure approvals, and advancing engineering and pre-development works in Brazil.

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.